Given that alternative treatments exist for both rheumatologic diseases and gout, it would thus be reasonable to use a fairly low diagnostic threshold (5% of LC3- or p62-positive fibers) for recommendation to discontinue hydroxychloroquine or colchicine therapy in a symptomatic patient with otherwise equivocal pathologic findings. This evidence concerns the gene MAP1LC3A and gout.